EA201491754A1 - Вакцина против rsv - Google Patents

Вакцина против rsv

Info

Publication number
EA201491754A1
EA201491754A1 EA201491754A EA201491754A EA201491754A1 EA 201491754 A1 EA201491754 A1 EA 201491754A1 EA 201491754 A EA201491754 A EA 201491754A EA 201491754 A EA201491754 A EA 201491754A EA 201491754 A1 EA201491754 A1 EA 201491754A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine against
against rsv
rsv
nucleic acid
acid encoding
Prior art date
Application number
EA201491754A
Other languages
English (en)
Other versions
EA026504B1 (ru
Inventor
Катарина Радошевич
Жером Х.Х.В. Кустерс
Йорт Веллинга
Мира Н. Виджожоатмоджо
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA201491754A1 publication Critical patent/EA201491754A1/ru
Publication of EA026504B1 publication Critical patent/EA026504B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Настоящее изобретение относится к вакцине против респираторно-синцитиального вируса (RSV), содержащей рекомбинантный аденовирус человека серотипа (26), который содержит нуклеиновую кислоту, кодирующую белок F RSV или его иммунологически активную часть.
EA201491754A 2012-03-22 2013-03-21 Вакцина против rsv EA026504B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22
PCT/EP2013/055935 WO2013139911A1 (en) 2012-03-22 2013-03-21 Vaccine against rsv

Publications (2)

Publication Number Publication Date
EA201491754A1 true EA201491754A1 (ru) 2014-12-30
EA026504B1 EA026504B1 (ru) 2017-04-28

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201491754A EA026504B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv
EA201491752A EA026620B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201491752A EA026620B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv

Country Status (15)

Country Link
EP (2) EP2827894B1 (ru)
JP (2) JP5845376B2 (ru)
KR (2) KR102023791B1 (ru)
CN (2) CN105431169B (ru)
AP (2) AP2014007994A0 (ru)
AR (2) AR090469A1 (ru)
AU (2) AU2013237429B2 (ru)
BR (1) BR112014023196B1 (ru)
CA (2) CA2867950C (ru)
EA (2) EA026504B1 (ru)
MY (2) MY169331A (ru)
NZ (2) NZ630649A (ru)
SG (2) SG11201405803PA (ru)
TW (2) TWI640534B (ru)
WO (2) WO2013139911A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211756T1 (hr) 2012-07-05 2022-02-18 Glaxosmithkline Biologicals Sa Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi
KR20150139954A (ko) * 2013-04-08 2015-12-14 메디뮨 엘엘씨 백신 조성물 및 사용 방법
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2988654A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
EP3393512A1 (en) 2015-12-23 2018-10-31 Pfizer Inc Rsv f protein mutants
SG11201807912SA (en) * 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
EA039095B1 (ru) 2016-04-05 2021-12-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-белки rsv до слияния
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) * 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
US20220273787A1 (en) * 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
KR20220008816A (ko) * 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
CN115605224A (zh) 2020-05-12 2023-01-13 扬森疫苗与预防公司（Nl） 同源腺病毒载体的施用
EA037297B9 (ru) * 2020-08-22 2021-11-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты)
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
BR112022003581A2 (pt) * 2020-08-22 2022-08-16 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Vetor de expressão contra o vírus da síndrome respiratória aguda grave sars-cov-2
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
WO2022215436A1 (ja) * 2021-04-05 2022-10-13 株式会社クボタ 管理機制御システム
CN117018175A (zh) * 2022-05-10 2023-11-10 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
BR9710030A (pt) 1996-07-01 1999-08-10 Rhone Poulenc Rorer Sa Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
JP4358434B2 (ja) 1998-02-17 2009-11-04 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US20020041884A1 (en) 2000-03-07 2002-04-11 Evans Robert K. Adenovirus formulations
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
IL162404A0 (en) 2002-01-18 2005-11-20 Schering Ag Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
DK1506287T3 (da) 2002-05-14 2007-08-20 Merck & Co Inc Fremgangsmåder til oprensning af adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP4749334B2 (ja) * 2003-10-02 2011-08-17 クルセル ホランド ベー ヴェー 組換えアデノウイルス用パッケージング細胞
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
CA2567094C (en) * 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
EP1851343A2 (en) * 2005-02-11 2007-11-07 Merck and Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
JP5465331B2 (ja) 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー 高細胞密度の培養物からのアデノウイルスの精製方法
EP2496609A4 (en) * 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
BR112014023196A2 (ru) 2017-06-20
TW201343669A (zh) 2013-11-01
EP2827895B1 (en) 2017-08-09
EP2827895A1 (en) 2015-01-28
AU2013237424B2 (en) 2017-07-06
SG11201405804YA (en) 2014-10-30
MY169331A (en) 2019-03-21
CN105431169A (zh) 2016-03-23
CA2867955A1 (en) 2013-09-26
AU2013237424A1 (en) 2014-10-16
TWI624545B (zh) 2018-05-21
AR090469A1 (es) 2014-11-12
NZ630753A (en) 2016-12-23
EP2827894A1 (en) 2015-01-28
KR102050616B1 (ko) 2019-12-03
CN105431169B (zh) 2019-04-02
CN104334188A (zh) 2015-02-04
AP2014007993A0 (en) 2014-10-31
SG11201405803PA (en) 2014-11-27
KR20140138769A (ko) 2014-12-04
TWI640534B (zh) 2018-11-11
WO2013139916A1 (en) 2013-09-26
JP5845376B2 (ja) 2016-01-20
AU2013237429A1 (en) 2014-10-09
JP5805908B2 (ja) 2015-11-10
AP2014007994A0 (en) 2014-10-31
BR112014023196B1 (pt) 2021-09-08
EA026504B1 (ru) 2017-04-28
CA2867955C (en) 2023-02-07
EA201491752A1 (ru) 2015-02-27
JP2015512380A (ja) 2015-04-27
TW201341531A (zh) 2013-10-16
EA026620B1 (ru) 2017-04-28
KR20140138765A (ko) 2014-12-04
CN104334188B (zh) 2016-08-24
CA2867950A1 (en) 2013-09-26
MY169352A (en) 2019-03-25
NZ630649A (en) 2016-12-23
CA2867950C (en) 2023-02-21
AR090470A1 (es) 2014-11-12
WO2013139911A1 (en) 2013-09-26
EP2827894B1 (en) 2017-05-17
JP2015519295A (ja) 2015-07-09
KR102023791B1 (ko) 2019-09-23
AU2013237429B2 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
EA201491754A1 (ru) Вакцина против rsv
EA201892250A1 (ru) Вакцина против rsv
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
PH12018500856A1 (en) Respiratory syncytial virus vaccine
WO2018089851A3 (en) Influenza vaccine
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
EA201390866A1 (ru) Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
DK1881845T3 (da) Nipah-virusvacciner
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
HK1205459A1 (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine (mva)(rsv)
WO2012021730A3 (en) Respiratory syncytial virus (rsv) vaccine
WO2015052543A3 (en) Malaria vaccination
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
WO2015041924A8 (en) Recombinant respiratory syncytial virus (rsv) and vaccines
PH12014502013A1 (en) Vaccine against rsv
ZA201500606B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
DK3436053T3 (da) Formuleringer, som omfatter rekombinant syre-alfa-glucosidase

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM